Please assess the completion status of the following clinical trial:

Trial Title: Tegafur-Uracil and Leucovorin or S-1 in Treating Patients With Stage III Colon Cancer That Has Been Completely Removed by Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed adenocarcinoma of colon~  * Stage III (T1-4, N1-3, M0) disease~* Has undergone surgical resection of the tumor within the past 8 weeks~PATIENT CHARACTERISTICS:~* ECOG performance status 0-1~* Able to take medications orally~* WBC ≥ 3,500/mm³ and \< 12,000/mm³~* ANC ≥ 1,500/mm³~* Platelet count ≥ 100,000/mm³~* Hemoglobin ≥ 9.0 g/dL~* Total bilirubin ≤ 2.0 mg/dL~* AST/ALT ≤ 100 IU/L~* Creatinine ≤ 1.2 mg/dL~* No other active malignancies~* Must have none of the following comorbidities:~  * Severe postoperative complications~ * Uncontrollable diabetes mellitus~ * Uncontrollable hypertension~ * Myocardial infraction within 6 months~ * Unstable angina pectoris~ * Hepatocirrhosis~ * Interstitial pneumonia, pulmonary fibrosis, or severe emphysema~PRIOR CONCURRENT THERAPY:~* No prior chemotherapy or radiotherapy for colon cancer~* No concurrent radiotherapy~* No concurrent biological response modifiers

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- tegafur-gimeracil-oteracil potassium (Type: EXPERIMENTAL): Patients receive tegafur-gimeracil-oteracil potassium(S-1) orally twice daily for 28 days with a subsequent pause of 14 days. This repeats 4 times every 6 weeks.
- tegafur-uracil and folinate calcium (Type: ACTIVE_COMPARATOR): Patients receive tegafur-uracil(UFT) plus folinate calcium(leucovorin) orally every 8 hours for 21 days with a subsequent pause of 7 days. This repeats 5 times every 5 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).